JP2016516076A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516076A5
JP2016516076A5 JP2016503654A JP2016503654A JP2016516076A5 JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5 JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
insulin
chain
long
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516076A (ja
JP6755175B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055533 external-priority patent/WO2014147141A1/en
Publication of JP2016516076A publication Critical patent/JP2016516076A/ja
Publication of JP2016516076A5 publication Critical patent/JP2016516076A5/ja
Application granted granted Critical
Publication of JP6755175B2 publication Critical patent/JP6755175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503654A 2013-03-20 2014-03-19 インスリン投薬レジメン Active JP6755175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13160194 2013-03-20
EP13160194.0 2013-03-20
US201361804363P 2013-03-22 2013-03-22
US61/804,363 2013-03-22
PCT/EP2014/055533 WO2014147141A1 (en) 2013-03-20 2014-03-19 Insulin dosing regimen

Publications (3)

Publication Number Publication Date
JP2016516076A JP2016516076A (ja) 2016-06-02
JP2016516076A5 true JP2016516076A5 (https=) 2017-04-27
JP6755175B2 JP6755175B2 (ja) 2020-09-16

Family

ID=47900938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503654A Active JP6755175B2 (ja) 2013-03-20 2014-03-19 インスリン投薬レジメン

Country Status (5)

Country Link
US (4) US20160296602A1 (https=)
EP (1) EP2976096B1 (https=)
JP (1) JP6755175B2 (https=)
CN (1) CN105188736A (https=)
WO (1) WO2014147141A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー/エス インスリン組成物および組成物の製造方法
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー/エス 新規投与レジメン
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
MA46890A (fr) * 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
WO2018096162A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
WO2020002428A1 (en) * 2018-06-26 2020-01-02 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
SG11202106167XA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin conjugates
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
SI2107069T1 (sl) * 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
JP4808785B2 (ja) * 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー/エス インスリン組成物および組成物の製造方法
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2178910B1 (en) * 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
AU2009309623B9 (en) * 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US20130143803A1 (en) * 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN103167878A (zh) * 2010-10-27 2013-06-19 诺沃—诺迪斯克有限公司 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
AU2012213432B2 (en) * 2011-02-01 2016-10-13 Novo Nordisk A/S Purification of insulin
AU2012223282B2 (en) * 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
CA2872083A1 (en) * 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
JP2016519127A (ja) * 2013-04-30 2016-06-30 ノヴォ ノルディスク アー/エス 新規投与レジメン

Similar Documents

Publication Publication Date Title
JP2016516076A5 (https=)
DK1965823T3 (en) Methods of administering hypoglycemics
RU2011117645A (ru) Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
Melson et al. Future therapies for obesity
RU2419452C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ hGLP-1, ЭКСЕНДИНА-4 И ИХ АНАЛОГОВ
JP2007523881A5 (https=)
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
JP2014520798A5 (https=)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
JP2011241213A5 (https=)
JP2011001381A (ja) Glp−1医薬組成物
WO2009020802A2 (en) Treatment for obesity
JP2014520798A (ja) ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
JP2013526501A5 (https=)
Brandt et al. Are peptide conjugates the golden therapy against obesity?
JP2015517458A5 (https=)
Edmonds et al. Oral GLP-1 modulators for the treatment of diabetes
RU2014147674A (ru) Фармацевтическая композиция
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus
JP2014500244A5 (https=)
JP6049625B2 (ja) 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
Shibata et al. Effect of glucagon, glicentin, glucagon-like peptide-1 and-2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch
Lee et al. Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact